Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox vs Scopoderm for Drooling in Children With Cerebral Palsy
NCT03616067Phase 3Terminated
- Sponsor
- Hospices Civils de Lyon
- Start
- Apr 2022
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of botulinum toxin type A in sialorrhea (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Drooling Impact Scale at 15 months. Started Apr 2022; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
sialorrhea
Beyond the preview
Go deeper on NCT03616067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03616067.